SCHEMBL4288992

SCHEMBL4288992

O=c1[nH]ncc2ccc3ccccc3c12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
HSD17B10 Q99714 4/20 0.67
TDP1 Q9NUW8 4/20 0.67
PARP1 P09874 2/20 0.67
PRKCI P41743 1/20 0.67
PDE4B Q07343 1/20 0.67
MAPK1 P28482 2/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 1/20 0.49
TYMS P04818 2/20 0.46
HSP90AA1 P07900 1/20 0.44
IDO1 P14902 1/20 0.44
CDK2 P24941 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PAX8 Q06710 1/20 0.39
CYP2A6 P11509 1/20 0.39
TSHR P16473 1/20 0.39
ABCB1 P08183 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phthalazinone SCHEMBL51553 0.80 PARP1 (1.00) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL2962226 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL2473799 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL11516875 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL11690359 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL11519244 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL9617397 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL4663241 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL11516881 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI
Phthalazinone SCHEMBL11519239 0.79 PARP1 (0.96) ALDH1A1HSD17B10TDP1PARP1PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
EP-1904449-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-04-02 EP disclosed
CN-101005844-A Muscarinic antagonists with PARP and SIR modulatng activity as agents for inflammatory diseases PROTEOSYS AG (DE) 2007-07-25 CN disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A ALDH1A1 2405/4885HSD17B10 4115/4885TDP1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.